Bleeding Academic Research Consortium: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Bleeding Academic Research Consortium Definition for Bleeding''' | |||
*'''Type 0''': no bleeding | *'''Type 0''': no bleeding | ||
| Line 19: | Line 21: | ||
*'''Type 5a''': Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious | *'''Type 5a''': Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious | ||
<ref name="pmid21670242">{{cite journal| author=Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al.| title=Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. | journal=Circulation | year= 2011 | volume= 123 | issue= 23 | pages= 2736-47 | pmid=21670242 | doi=10.1161/CIRCULATIONAHA.110.009449 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21670242 }} </ref> | |||
*'''Type 5b''': Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation | *'''Type 5b''': Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation | ||
Revision as of 20:33, 16 June 2011
Bleeding Academic Research Consortium Definition for Bleeding
- Type 0: no bleeding
- Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a health-care professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a health-care professional.
- Type 2: any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a health-care professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation
- Type 3
- Type 3a: Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL* (provided hemoglobin drop is related to bleed)Any transfusion with overt bleeding
- Type 3b: Overt bleeding plus hemoglobin drop more than or equal to 5 g/dL* (provided hemoglobin drop is related to bleed)Cardiac tamponade, Bleeding requiring surgical intervention for control (excludingdental/nasal/skin/hemorrhoid), Bleeding requiring intravenous vasoactive agents
- Type 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), Subcategories confirmed by autopsy or imaging or lumbar puncture, Intraocular bleed compromising vision.
- Type 4: CABG-related bleeding, Perioperative intracranial bleeding within 48 h, Reoperation after closure of sternotomy for the purpose of controlling bleeding
Transfusion of more than equal to 5 U whole blood or packed red blood cells within a 48-h period, Chest tube output more than or equal to 2L within a 24-h period
- Type 5: fatal bleeding
- Type 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious
- Type 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation
- ↑ Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J; et al. (2011). "Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium". Circulation. 123 (23): 2736–47. doi:10.1161/CIRCULATIONAHA.110.009449. PMID 21670242.